Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Key highlights

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 170 Press Releases

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Press Release Icon  –  22 April 2024

22 April 2024

Download
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…


Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Press Release Icon  –  02 April 2024

02 April 2024

Download
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…


Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Press Release Icon  –  15 February 2024

15 February 2024

Download
Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Attachment


Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Press Release Icon  –  13 February 2024

13 February 2024

Download
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as…


Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Press Release Icon  –  08 February 2024

08 February 2024

Download
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.


Your dedicated contacts

Related links